Press Releases
GT Biopharma Announces Preclinical Results For Its ROR1 TriKE™ As A Treatment For Prostate Cancer
GT Biopharma Adds University of Wisconsin--Madison Carbone Cancer Center as Second Site in Ongoing Phase 1/2 Clinical Trial of GTB-3550 TriKE™, a Novel NK Cell Therapeutic Cancer Treatment
GT Biopharma Transfers TriKE™ Manufacturing To Cytovance Biologics In Preparation For Expanded And Multiple Liquid And Solid Tumor Clinical Trials
GT Biopharma Announces Closing of $23.7 Million Public Offering
GT Biopharma Announces Pricing of $23,650,000 Public Offering and Uplisting to The Nasdaq Capital Market
GT Biopharma Appoints Two New Independent Directors
GT Biopharma Announces Eighth Patient Begins Treatment Of GTB-3550
GT Biopharma (OTCQB: GTBP) Announces Corporate Update Conference Call
- « Previous
- 1
- 2
- 3
- 4